The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ASSEMBLY BIOSCIENCES | COM | 045396108 | 20,841 | 1,574,107 | SH | SOLE | 1,574,107 | 0 | 0 | ||
ATARA BIOTHERAPEUTICS | COM | 046513107 | 44,197 | 1,063,189 | SH | SOLE | 1,063,189 | 0 | 0 | ||
CALITHERA BIOSCIENCES | COM | 13089P101 | 4,852 | 295,480 | SH | SOLE | 295,480 | 0 | 0 | ||
CLOVIS ONCOLOGY | COM | 189464100 | 18,041 | 243,048 | SH | SOLE | 243,048 | 0 | 0 | ||
EPIZYME | COM | 29428V104 | 29,680 | 1,580,400 | SH | SOLE | 1,580,400 | 0 | 0 | ||
FIBROGEN | COM | 31572Q808 | 12,552 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
FLEX PHARMA | COM | 33938A105 | 15,792 | 805,691 | SH | SOLE | 805,691 | 0 | 0 | ||
FLEXION THERAPEUTICS | COM | 33938J106 | 3,669 | 162,900 | SH | SOLE | 162,900 | 0 | 0 | ||
FORWARD PHARMA A/S SPONSORED ADR | SPONSORED ADR | 34986J105 | 4,502 | 158,985 | SH | SOLE | 158,985 | 0 | 0 | ||
GENVEC | COM | 37246C307 | 5,860 | 1,986,413 | SH | SOLE | 1,986,413 | 0 | 0 | ||
IRONWOOD PHARMACEUTICALS CL A | COM CL A | 46333X108 | 14,400 | 900,000 | SH | SOLE | 900,000 | 0 | 0 | ||
KINDRED BIOSCIENCES | COM | 494577109 | 9,242 | 1,294,431 | SH | SOLE | 1,294,431 | 0 | 0 | ||
KITE PHARMA | COM | 49803L109 | 16,231 | 281,400 | SH | SOLE | 281,400 | 0 | 0 | ||
RECEPTOS | COM | 756207106 | 24,948 | 151,301 | SH | SOLE | 151,301 | 0 | 0 | ||
RETROPHIN | COM | 761299106 | 9,824 | 410,000 | SH | SOLE | 410,000 | 0 | 0 | ||
SAGE THERAPEUTICS INC | COM | 78667J108 | 5,649 | 112,455 | SH | SOLE | 112,455 | 0 | 0 | ||
TARGACEPT | COM | 87611R306 | 1,841 | 619,699 | SH | SOLE | 619,699 | 0 | 0 | ||
XENON PHARMACEUTICALS | COM | 98420N105 | 3,720 | 220,570 | SH | SOLE | 220,570 | 0 | 0 | ||
ARRAY BIOPHARMA SR CONV NT 3.000% Due 06/01/2020 | NOTE | 04269XAA3 | 21,973 | 17,500,000 | PRN | SOLE | 17,500,000 | 0 | 0 | ||
ARRAY BIOPHARMA | COM | 04269X105 | 1,548 | 2,100 | SH | Call | SOLE | 2,100 | 0 | 0 | |
ARRAY BIOPHARMA | COM | 04269X105 | 3,869 | 5,250 | SH | Call | SOLE | 5,250 | 0 | 0 | |
CLOVIS ONCOLOGY | COM | 189464950 | 18,558 | 2,500 | SH | Put | SOLE | 2,500 | 0 | 0 | |
EPIZYME | COM | 29428V904 | 282 | 150 | SH | Call | SOLE | 150 | 0 | 0 | |
IRONWOOD PHARMACEUTICALS CL A | COM CL A | 46333X108 | 8,000 | 5,000 | SH | Call | SOLE | 5,000 | 0 | 0 |